Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Novartis building

Novartis lifts 2013 guidance on delay to Diovan generics

Reveals scale of payments to former CEO Daniel Vasella

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

Novartis day

Lucentis cleared in Europe for pathological myopia

Makes Novartis' drug the first anti-VEGF approved in this setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links